

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
26 January 2023 (26.01.2023)



(10) International Publication Number
WO 2023/004326 A1

(51) International Patent Classification:

C07K 16/28 (2006.01) A61P 35/00 (2006.01)
A61K 35/17 (2015.01) C07K 16/46 (2006.01)
A61K 39/395 (2006.01)

(21) International Application Number:

PCT/US2022/073903

(22) International Filing Date:

19 July 2022 (19.07.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/223,473 19 July 2021 (19.07.2021) US

(71) Applicant (for all designated States except US):

UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
[US/US]; 1st Floor Gardner Steel Conference Center, 130 Thackeray Avenue, Pittsburgh, Pennsylvania 15260 (US).

(72) Inventors; and


(71) Applicants (for US only): **DELGOFFE, Greg, M.**
[US/US]; c/o University of Pittsburgh, 130 Thackeray Ave., 1st Floor GSCC, Pittsburgh, Pennsylvania 15260 (US).
PERALTA, Ronal [US/US]; c/o University of Pittsburgh, 130 Thackeray Ave., 1st Floor GSCC, Pittsburgh, Pennsylvania 15260 (US).

(74) Agent: **THIREAULT, Caitlin, A.** et al.; Klarquist, One World Trade Center, Suite 1600, 121 SW Salmon Street, Portland, Oregon 97204 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,

(54) Title: MCT11 ANTIBODIES TO TREAT T CELL FUNCTIONAL EXHAUSTION AND ENHANCE CANCER IMMUNOTHERAPY

FIG. 1



(57) Abstract: Monoclonal antibodies and antigen binding fragments that specifically bind MCT11 are provided. Also disclosed are nucleic acid molecules encoding the antibody, vectors including these nucleic acid molecules, and host cells transfected with these vectors. Methods of using MCT11 specific antibodies to treat cancer, inhibit or treat T cell exhaustion, and/or enhance immunotherapy, are also provided.

[Continued on next page]

TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

- *with international search report (Art. 21(3))*
- *with sequence listing part of description (Rule 5.2(a))*